FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2037495557> ?p ?o ?g. }

• W2037495557 endingPage "7" @default.
• W2037495557 startingPage "5a" @default.
• W2037495557 abstract "Back to table of contents Previous article Next article Professional NewsFull AccessLook for Comorbidities in Youth With AddictionAaron LevinAaron LevinSearch for more papers by this authorPublished Online:15 Jun 2012https://doi.org/10.1176/pn.47.12.psychnews_47_12_5-aAbstractSubstance use is increasing among adolescents, yet existing psychosocial interventions to treat related disorders have shown only modest efficacy.From left: Aaron Hogue, Ph.D., of Columbia University; Kevin Gray, M.D., of the Medical University of South Carolina; and Paula Riggs, M.D., of the University of Colorado School of Medicine discuss new developments in the treatment of adolescents with substance abuse at APA’s 2012 annual meeting in Philadelphia. Comorbidities are common, said Riggs, and treating them may be key to successful treatment of substance abuse.David Hathcox“Adolescents are more vulnerable to addiction in part because of rapid brain development that continues up to the mid-20s,” said Paula Riggs, M.D., a professor of psychiatry and director of the Division of Substance Dependence at the University of Colorado School of Medicine in Denver, at APA’s 2012 annual meeting in Philadelphia in May. “Whatever a teenager does affects brain development and pruning.”Thus, addiction and mental illness frequently both have pediatric-onset and developmental contexts, and each is a risk factor for the other, she said.Despite its benign reputation among the general public, marijuana is especially bad for adolescents because it disrupts development of the prefrontal cortex by way of the CB1 receptor’s regulatory role, she explained.In addition, marijuana alters the reward response to other drugs, disrupts control over glutamate and GABA of the endogenous cannabinoid system, and can predispose vulnerable individuals to schizophrenia and other psychoses.Treatment can be effective, but only about 10 percent of those who need it access care. Too often it produces only modest reductions in drug use, low abstinence, and high relapse rates.One reason for the lack of success in treatment is that comorbidity is common, but treatments integrating behavioral and pharmacotherapy are few, she noted. Many adolescents would also benefit from early intervention, but most are physically healthy and see primary care clinicians too rarely.Comorbidities may be a key to treating the substance abuse.Riggs cited several clinical trials that combined medications with cognitive-behavioral therapy (CBT) to treat patients with drug use and other psychiatric comorbidities (like depression or ADHD). One tested fluoxetine and 16 weeks of CBT versus placebo plus CBT. Although depression remitted more often in patients treated with fluoxetine/CBT (70 percent) compared to placebo/CBT (52 percent), rates of depression remission were higher than expected in both groups, which suggests that CBT targeting substance abuse may have contributed to depression treatment response, said Riggs.Furthermore, patients whose depression remitted, regardless of treatment group, significantly reduced their drug use, while nonremittters did not.“Depression remission may be important to substance treatment outcomes,” she said. “So if depression symptoms don’t significantly decline at the end of the first month of substance treatment, fluoxetine should be considered—and closely monitored—because it appears to be safe and effective even in those not yet abstinent.”Another similarly designed study indicated that OROS-methylphenidate may be both safe and beneficial for ADHD in adolescents concurrently receiving CBT substance treatment, she said. Results of this study also showed greater improvement in some substance treatment outcomes (such as more negative urine drug screens or more days abstinent) in those whose ADHD was treated with OROS/methylphenidate with CBT compared with placebo plus CBT.An integrated treatment approach should begin with a comprehensive psychiatric and substance use diagnostic assessment, including a structured evaluation such as with the Kiddie-Schedule for Affective Disorders and Schizophrenia (KSADS), said Riggs.“Map the temporal and developmental relationships between the onset and progression of substance abuse and psychiatric symptoms,” she said. “Ask about regular use, prior month use, and last use to differentiate use and dependency.”Treatment should begin with nonpharmacological approaches and then proceed, if needed, to monotherapy with proven medications, like fluoxetine, OROS, or naltrexone, depending on the substance. Monitor side effects and compliance, Riggs advised.“Think parsimony and monotherapy,” she said. “I don’t like to see kids on three or four drugs.”Finally, clinicians should work to get the adolescent involved in “pro-social, no-drug activities” to help the young brain develop.Future research should test the efficacy on psychiatric symptoms of CBT targeting substance abuse, she emphasized. Better validated psychological measures and more sophisticated analytic methods are needed, as well. More research on earlier intervention—especially in nontraditional settings like schools—and the medical cost savings that would result would also help.Above all, said Riggs, “We need a comprehensive, team approach using existing community resources.” Watch a video interview with Riggs on YouTube at http://www.youtube.com/watch?v=C301EYY1W9Y. ISSUES NewArchived" @default.
• W2037495557 created "2016-06-24" @default.
• W2037495557 creator A5048305459 @default.
• W2037495557 date "2012-06-15" @default.
• W2037495557 modified "2023-10-17" @default.
• W2037495557 title "Look for Comorbidities in Youth With Addiction" @default.
• W2037495557 doi "https://doi.org/10.1176/pn.47.12.psychnews_47_12_5-a" @default.
• W2037495557 hasPublicationYear "2012" @default.
• W2037495557 type Work @default.
• W2037495557 sameAs 2037495557 @default.
• W2037495557 citedByCount "0" @default.
• W2037495557 crossrefType "journal-article" @default.
• W2037495557 hasAuthorship W2037495557A5048305459 @default.
• W2037495557 hasConcept C118552586 @default.
• W2037495557 hasConcept C150966472 @default.
• W2037495557 hasConcept C15744967 @default.
• W2037495557 hasConcept C27415008 @default.
• W2037495557 hasConcept C40010229 @default.
• W2037495557 hasConcept C48856860 @default.
• W2037495557 hasConcept C71924100 @default.
• W2037495557 hasConceptScore W2037495557C118552586 @default.
• W2037495557 hasConceptScore W2037495557C150966472 @default.
• W2037495557 hasConceptScore W2037495557C15744967 @default.
• W2037495557 hasConceptScore W2037495557C27415008 @default.
• W2037495557 hasConceptScore W2037495557C40010229 @default.
• W2037495557 hasConceptScore W2037495557C48856860 @default.
• W2037495557 hasConceptScore W2037495557C71924100 @default.
• W2037495557 hasIssue "12" @default.
• W2037495557 hasLocation W20374955571 @default.
• W2037495557 hasOpenAccess W2037495557 @default.
• W2037495557 hasPrimaryLocation W20374955571 @default.
• W2037495557 hasRelatedWork W1560136702 @default.
• W2037495557 hasRelatedWork W2062793856 @default.
• W2037495557 hasRelatedWork W2112427368 @default.
• W2037495557 hasRelatedWork W2151347485 @default.
• W2037495557 hasRelatedWork W2892767813 @default.
• W2037495557 hasRelatedWork W2896432742 @default.
• W2037495557 hasRelatedWork W3039046587 @default.
• W2037495557 hasRelatedWork W328990708 @default.
• W2037495557 hasRelatedWork W329183168 @default.
• W2037495557 hasRelatedWork W1504405748 @default.
• W2037495557 hasVolume "47" @default.
• W2037495557 isParatext "false" @default.
• W2037495557 isRetracted "false" @default.
• W2037495557 magId "2037495557" @default.
• W2037495557 workType "article" @default.